Ascentage Pharma Group International (AAPG)vsargenx NV ADR (ARGX)
AAPG
Ascentage Pharma Group International
$21.66
+0.74%
HEALTHCARE · Cap: $2.01B
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 726% more annual revenue ($4.74B vs $574.12M). ARGX leads profitability with a 31.4% profit margin vs -216.5%. ARGX earns a higher WallStSmart Score of 75/100 (B).
AAPG
Avoid29
out of 100
Grade: F
ARGX
Strong Buy75
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.8%
Fair Value
$26.39
Current Price
$21.66
$4.73 discount
Margin of Safety
+64.2%
Fair Value
$2329.77
Current Price
$782.17
$1547.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 117.0% year-over-year
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Areas to Watch
Trading at 10.4x book value
0.0% earnings growth
Weak financial health signals
ROE of -154.6% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Piotroski F-Score.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
AAPG profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.72 — expect wider price swings.
AAPG is growing revenue faster at 117.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (75/100 vs 29/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?